RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network. The ...

RNA, widely known from the COVID-19 vaccine, is not actually a “therapeutic agent,” but a technology that delivers the ...

BIOVECTRA and Revolution Biomanufacturing partner to integrate mRNA sequence design with end-to-end GMP manufacturing for faster development.

A new approach has been proposed to suppress the side effects of messenger ribonucleic acid (mRNA), opening up possibilities ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing self-sufficiency and efficiency in drug production. The expansion will create ...

Researchers found that using mental models—visual, verbal, or animated—helps people understand mRNA vaccination science, counter misconceptions, and reduce misinformation spread.

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional ...

Researchers at LMU have uncovered how ribosomes, the cell’s protein builders, also act as early warning sensors when something goes wrong inside a cell. When protein production is disrupted, and ...